Items in FPM with MESH term: Physician's Practice Patterns

Pages: Previous 1 2 3 4 5 6 7 8 Next

Oral Health in Primary Care Medicine: Practice and Policy Challenges - Editorials

Delaying Antibiotics for Respiratory Infections - Cochrane for Clinicians

Antibiotics for Acute Laryngitis in Adults - Cochrane for Clinicians

Physicians Who Do Not Follow Screening Guidelines - Curbside Consultation

U.S. Statin Guidelines: Expensive but Not Necessarily Effective - Editorials

New USPSTF Resources and Tools Can Help Put Prevention into Your Practice - Editorials

Noninfectious Penile Lesions - Article

ABSTRACT: Family physicians commonly diagnose and manage penile cutaneous lesions. Noninfectious lesions may be classified as inflammatory and papulosquamous (e.g., psoriasis, lichen sclerosus, angiokeratomas, lichen nitidus, lichen planus), or as neoplastic (e.g., carcinoma in situ, invasive squamous cell carcinoma). The clinical presentation and appearance of the lesions guide the diagnosis. Psoriasis presents as red or salmon-colored plaques with overlying scales, often with systemic lesions. Lichen sclerosus presents as a phimotic, hypopigmented prepuce or glans penis with a cellophane-like texture. Angiokeratomas are typically asymptomatic, well-circumscribed, red or blue papules, whereas lichen nitidus usually produces asymptomatic pinhead-sized, hypopigmented papules. The lesions of lichen planus are pruritic, violaceous, polygonal papules that are typically systemic. Carcinoma in situ should be suspected if the patient has velvety red or keratotic plaques of the glans penis or prepuce, whereas invasive squamous cell carcinoma presents as a painless lump, ulcer, or fungating irregular mass. Some benign lesions, such as psoriasis and lichen planus, can mimic carcinoma in situ or squamous cell carcinoma. Biopsy is indicated if the diagnosis is in doubt or neoplasm cannot be excluded. The management of benign penile lesions usually involves observation or topical corticosteroids; however, neoplastic lesions generally require surgery.

Evaluating the Safety and Effectiveness of New Drugs - Article

ABSTRACT: Prescribers seek to provide their patients with access to the latest innovations in medicine to maximize their health status. When a new drug comes to market, it often has not been as widely tested as other available therapies, and its effectiveness and safety cannot be fully evaluated. To address this problem, physicians can use the STEPS (Safety, Tolerability, Effectiveness, Price, and Simplicity) mnemonic to provide an analytic framework for making better decisions about a new drug’s appropriate place in therapy. A key element is to base this evaluation on patientoriented evidence rather than accept disease-oriented evidence (which may be misleading), while avoiding inappropriate reliance on studies that report only noninferiority results or relative risk reductions. The primary question to ask for each new drug prescribing decision is, “Is there good evidence that this new drug is likely to make my patient live longer or better compared with the available alternatives?” (Am Fam Physician. 2010;82(1):53-57. Copyright © 2010 American Academy of Family Physicians.)

Prescribing Evidence: The Effectiveness and Safety of New Drugs - Editorials

Evidence for Global CHD Risk Calculation: Risk Assessment Alone Does Not Change Outcomes - Editorials

Pages: Previous 1 2 3 4 5 6 7 8 Next


Information From Industry